石药创新：SYS6010再获突破性治疗认定 III期临床试验正在开展

同花顺09-15 19:08

中证智能财讯石药创新（300765）(300765)9月15日晚间公告，公司控股子公司石药集团（HK1093）巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，拟定适应症为免疫及含铂化疗治疗失败的复发或转移性驱动基因阴性非鳞非小细胞肺癌。据公告，该药物为靶向表皮生长因子受体(EGFR)的抗体偶联药物(ADC)，由人源化抗EGFR单克隆抗体通过可裂解...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2667264193?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-15 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667264193","market":"fut","top_or_hot":-1,"title":"石药创新：SYS6010再获突破性治疗认定 III期临床试验正在开展","media":"同花顺","content":"<div>\n<p>中证智能财讯石药创新（300765）(300765)9月15日晚间公告，公司控股子公司石药集团（HK1093）巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，拟定适应症为免疫及含铂化疗治疗失败的复发或转移性驱动基因阴性非鳞非小细胞肺癌。据公告，该药物为靶向表皮生长因子受体(EGFR)的抗体偶联药物(ADC)，由人源化抗EGFR单克隆抗体通过可裂解...</p>\n\n<a href=\"http://news.10jqka.com.cn/20260915/c679932866.shtml\">网页链接</a>\n\n</div>\n","source":"tonghuashun_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药创新：SYS6010再获突破性治疗认定 III期临床试验正在开展</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药创新：SYS6010再获突破性治疗认定 III期临床试验正在开展\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-15 19:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://news.10jqka.com.cn/20260915/c679932866.shtml><strong>同花顺</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中证智能财讯石药创新（300765）(300765)9月15日晚间公告，公司控股子公司石药集团（HK1093）巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，拟定适应症为免疫及含铂化疗治疗失败的复发或转移性驱动基因阴性非鳞非小细胞肺癌。据公告，该药物为靶向表皮生长因子受体(EGFR)的抗体偶联药物(ADC)，由人源化抗EGFR单克隆抗体通过可裂解...</p>\n\n<a href=\"http://news.10jqka.com.cn/20260915/c679932866.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSYK","symbol_name":"PSYK ETF","start_time":0,"source_url":"http://news.10jqka.com.cn/20260915/c679932866.shtml","article_id":"2667264193","we_media_id":null,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260915/c679932866.shtml","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2667264193","pubTimestamp":1789470480,"columns":[],"sourceInfo":{"source_id":"tonghuashun_highlight","name":"同花顺"},"weMediaInfo":null,"summary":"中证智能财讯石药创新(300765)9月15日晚间公告，公司控股子公司石药集团巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，拟定适应症为免疫及含 ...","collect":0,"end_time":0,"defaultTopTitle":"10jqka.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300765":"石药创新","PSYK":"PSYK ETF","MDTX":"Corgi MediaTek 2x Daily ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0226":"食品制造","BMED":"iShares Health Innovation Active ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF"},"translate_title":"CSPC Innovation: SYS6010 Receives Breakthrough Therapy Designation Again; Phase III Clinical Trials Underway","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300765":1.5,"PSYK":1.5,"MDTX":1.5,"BMED":1.5,"IBBJ":1.5,"IBBQ":1.5},"content_text":"中证智能财讯石药创新（300765）(300765)9月15日晚间公告，公司控股子公司石药集团（HK1093）巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，拟定适应症为免疫及含铂化疗治疗失败的复发或转移性驱动基因阴性非鳞非小细胞肺癌。据公告，该药物为靶向表皮生长因子受体(EGFR)的抗体偶联药物(ADC)，由人源化抗EGFR单克隆抗体通过可裂解连接子与拓扑异构酶I抑制剂载荷偶联而成，能够特异性结合肿瘤细胞表面的EGFR受体，经内化后在细胞内释放细胞毒性载荷，从而发挥抗肿瘤作用。公告披露，肺癌是全球癌症病例和死亡的首要病因。2024年我国肺癌新增约117.6万例，死亡约74.3万例，发病率和死亡率均居全球首位。非小细胞肺癌(NSCLC)是肺癌的主要病理亚型，占所有肺癌病例的85%。在NSCLC患者中，驱动基因阴性患者约占40%，且该人群发病率呈逐年上升趋势。免疫联合含铂化疗是驱动基因阴性NSCLC的一线标准治疗，一线失败后二线标准治疗仍为单药化疗，整体疗效不佳，患者生存获益有限。SYS6010临床价值突出，上市后可为患者提供更优治疗方案，未来市场潜力较大。目前，SYS6010单药用于经标准治疗失败的驱动基因阴性局部晚期或转移性非鳞非小细胞肺癌的随机、开放、多中心的III期临床试验正在开展。此前，SYS6010已获得药审中心授予的3项突破性治疗认定(不含本次)，拟定适应症分别为单药用于经EGFR-TKI和含铂化疗治疗失败的EGFR突变阳性晚期NSCLC、既往一线接受含铂化疗和免疫检查点抑制剂治疗后失败的不可切除的局部晚期或转移性食管鳞癌，以及经免疫和含铂化疗治疗失败的复发或转移性头颈鳞癌。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2667264193","isCrawlerRequest":true}